Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 1833 results for carers

  1. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)

    Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA883

  2. Psoriasis (QS40)

    This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    6 August 2013
    View quality statements

    Sections for QS40

  3. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    governance leads in their NHS trusts. Ensure that patients and their carers understand the uncertainty about the procedure's safety and...

    Research recommendation
    Published
    15 November 2019

  4. Alcohol-use disorders: prevention (PH24)

    This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.

    Public health guideline
    Published
    2 June 2010
    View recommendations

    Sections for PH24

  5. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    the committee agreed that children and young people and their families or carers should be empowered to take part in shared decision...

    Research recommendation
    Published
    25 October 2019

  6. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of family therapy, psychodynamic psychotherapy and interpersonal psychotherapy for adolescents (IPT‑A) compared with each other and with individual CBT in young people aged 12 to 18 years with moderate to severe depression?

    the committee agreed that children and young people and their families or carers should be empowered to take part in shared decision...

    Research recommendation
    Published
    25 October 2019

  7. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    the committee agreed that children and young people and their families or carers should be empowered to take part in shared decision...

    Research recommendation
    Published
    25 October 2019

  8. VA ECMO for severe acute heart failure in adults (HTG764)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

    HealthTech guidance
    Published
    22 October 2025
    View recommendations

    Sections for HTG764

  9. Screening assessment tools:- Develop reliable and valid screening assessment tools for attachment and sensitivity that can be made available and used in routine health, social care and education settings.

    can measure the sensitivity of parenting (by biological parents and new carers and adoptive parents) in relation to the child (of any...

    Research recommendation
    Published
    11 December 2015

  10. Interventions to reduce the frequency and extent of moderate to severe behaviour that challenges in community settings:- Are interventions based on the science and practice of applied behaviour analysis or antipsychotic medication, or a combination of these, effective in reducing the frequency and severity of behaviour that challenges shown by adults with a learning disability?

    disability and can have a considerable impact on them and their family members or carers. It is also a common reason for hospital or...

    Research recommendation
    Published
    5 October 2015

  11. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs

  12. Colorectal cancer (NG151)

    This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).

    NICE guideline
    Last updated
    15 December 2021
    View recommendations

    Sections for NG151

  13. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

    NICE guideline
    Published
    21 March 2024
    View recommendations

    Sections for NG241

  14. The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI raises no major safety concerns other than those associated with the TAVI procedure. However, the evidence on efficacy for preventing TAVI-related stroke is inconclusive. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    governance leads in their NHS trusts. Ensure that patients and their carers understand the procedure's safety and efficacy, as well as...

    Research recommendation
    Published
    15 November 2019

  15. Pharmacological interventions for anxiety disorders in people with learning disabilities who have autism:- What is the clinical and cost effectiveness and safety of pharmacological interventions for anxiety disorders in people with learning disabilities who have autism?

    of life for people with learning disabilities who have autism and their carers, as well as reducing costs to the NHS.Randomised...

    Research recommendation
    Published
    17 October 2016